Carol A Sherman

Title
InstitutionMedical University of South Carolina
DepartmentMedicine
AddressP.O. Box MSC 635
102
173 Ashley Ave.
Phone843-792-4271
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Stage III, Stage IV, Lung, Cancer, Cancer/Lung, Drug Studies

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704. PMID: 29628312.
      Citations:    
    2. Dimou A, Sherman C, Wrangle J. Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. J Thorac Imaging. 2016 Jul; 31(4):238-42. PMID: 27306389.
      Citations:    
    3. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015 Feb; 10(2):232-6. PMID: 25526238.
      Citations:    
    4. Tanner NT, Sherman CA, Silvestri GA. Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. Transl Lung Cancer Res. 2012 Jun; 1(2):96-8. PMID: 25806163.
      Citations:    
    5. Tanner NT, Pastis NJ, Sherman C, Simon GR, Lewin D, Silvestri GA. The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer. 2012 May; 76(2):131-7. PMID: 22176813.
      Citations:    
    6. Watkins JM, Zauls AJ, Kearney PL, Shirai K, Ruppert BN, Harper JL, Sherman CA, Aguero EG, Reed CE, Sharma AK. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Jpn J Clin Oncol. 2011 Mar; 41(3):334-42. PMID: 21084436.
      Citations:    
    7. Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9. PMID: 20958948.
      Citations:    
    8. Ruppert BN, Watkins JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, Sherman CA, Reed CE, Sharma AK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010 Aug; 33(4):346-52. PMID: 19841574.
      Citations:    
    9. Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT, Sharma AK. Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 2010 Jun; 28(5):340-8. PMID: 20585921.
      Citations:    
    10. Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1108-13. PMID: 19084345.
      Citations:    
    11. Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231. PMID: 18096059.
      Citations:    
    12. Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221. PMID: 18053191.
      Citations:    
    13. Urbanic JJ, Turrisi AT, Sharma AK, Silvestri GA, Williams TE, Vanek KN, Sherman CA. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis. J Thorac Oncol. 2006 Feb; 1(2):112-9. PMID: 17409839.
      Citations:    
    14. Sherman CA, Herndon JE, Watson DM, Green MR. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 2004 Sep; 45(3):387-92. PMID: 15301880.
      Citations:    
    15. Rocha Lima CM, Catapano CV, Pacheco D, Sherman CA, Oakhill G, Mushtaq C, Freeman KD, Green MR. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. Cancer. 2004 Jun 15; 100(12):2671-9. PMID: 15197811.
      Citations:    
    16. Mitas M, Hoover L, Silvestri G, Reed C, Green M, Turrisi AT, Sherman C, Mikhitarian K, Cole DJ, Block MI, Gillanders WE. Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003 Nov; 5(4):237-42. PMID: 14573783.
      Citations:    
    17. Turrisi AT, Bogart J, Sherman C, Silvestri G. The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease. Respir Care Clin N Am. 2003 Jun; 9(2):163-90. PMID: 12911288.
      Citations:    
    18. Frizzell B, Sinha D, Williams T, Reed CE, Sherman CA, Turrisi A. Influence of celiac axis lymph nodes in the definitive treatment of esophageal cancer. Am J Clin Oncol. 2003 Jun; 26(3):215-20. PMID: 12796587.
      Citations:    
    19. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6. PMID: 12733147.
      Citations:    
    20. Sherman CA, Turrisi AT, Wallace MB, Reed CE. Locally advanced esophageal cancer. Curr Treat Options Oncol. 2002 Dec; 3(6):475-85. PMID: 12392637.
      Citations:    
    21. Silvestri GA, Sherman C, Williams T, Leong SS, Flume P, Turrisi A. Caring for the dying patient with lung cancer. Chest. 2002 Sep; 122(3):1028-36. PMID: 12226050.
      Citations:    
    22. Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Green MR. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):19-24. PMID: 12109801.
      Citations:    
    23. Turrisi AT, Sherman CA. The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer. 2002 Jan; 38(2):279-91. PMID: 11803144.
      Citations:    
    24. Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):46-51. PMID: 11301841.
      Citations:    
    25. Rocha Lima CM, Urbanic JJ, Sherman CA, Brescia FJ, Green MR. Docetaxel followed by gemcitabine and irinotecan in solid tumors. Oncology (Williston Park). 2001 Jan; 15(1 Suppl 1):37-45. PMID: 11221020.
      Citations:    
    26. Green MR, Harper M, Safa A, Sherman CA, Mushtaq CM, Bahadori H, Brescia FJ, Rocha Lima CM. Irinotecan in the management of patients with pancreatic cancer. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):31-3. PMID: 11200146.
      Citations:    
    27. Green MR, Rocha Lima CM, Sherman CA. Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Semin Radiat Oncol. 2000 Oct; 10(4):289-95. PMID: 11040329.
      Citations:    
    28. Sherman CA, Rocha Lima CM, Turrisi AT. Limited small-cell lung cancer: a potentially curable disease. Oncology (Williston Park). 2000 Oct; 14(10):1395-403; discussion 1403-4, 1409. PMID: 11098505.
      Citations:    
    29. Cappuzzo F, Rocha Lima CM, Sherman CA, Green MR. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):7-14. PMID: 10960939.
      Citations:    
    30. Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Bahadori HR, Green MR. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol. 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2. PMID: 10585008.
      Citations:    
    31. Leong SS, Rocha Lima CM, Sherman CA, Green MR. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest. 1999 Jan; 115(1):242-8. PMID: 9925091.
      Citations:    
    Sherman's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (118)
    Explore
    _
    Co-Authors (16)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _